Adverse Event Reporting
|Number of vaccinations|
- Impaired work ability
- Muscular weakness
- Fine motor skill dysfunction
- Computerised tomogram neck
- Grip strength decreased
- Brachial plexus injury
Test Name: CT scan of neck; Result Unstructured Data: Test Result:it was normal
numbness and weakness in left arm; numbness and weakness in left arm; had a brachial plexus pathology; her grip and fine motor are affected in her left arm/she could not do her job; This is a spontaneous report from a contactable physician (patient).
A 35-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot# EH9899), via an unspecified route of administration in right arm on 21Dec2020 at single dose for Covid-19 immunisation.
Medical history included ongoing birth control.
No other medical history.
Concomitant drug included other medication she took for birth control.
On 29Dec2020, the patient experienced numbness and weakness in left arm, had a brachial plexus pathology, went to the emergency department on 30Dec2020 and was seen by one of the facility doctors and stated this doctor had her on steroids for treatment.
She got the vaccine in her right arm, stated her grip and fine motor are affected in her left arm.
States this was disabling since she could not do her job.
She was following up with neurology on Monday (unspecified), that she had a CT scan of her neck and it was normal.
Only other medication she was taking was for birth control, but she did not feel like it was relevant.
The outcome of events numbness and weakness in left arm was recovering, while outcome of other events was unknown.
This case was reported as serious, seriousness criteria was disabling.
; Sender's Comments: Based on the information currently provided, the vaccination with BNT162B2 might play a contributory role in triggering the onset of the reported events.
The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events.
Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.